Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "AREA[SponsorSearch](Denovo Biopharma LLC)"
Count: 18
Selected: 0
NCT05113771A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression
NCT03776071A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
NCT03263026Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™
NCT01659177A Study of LY2140023 in Healthy Participants
NCT01637142A Study of LY2140023 in Healthy Participants
NCT01609218A Study of LY2140023 in Healthy Participants
NCT01606436A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia
NCT01591330A Study of LY2140023 in Healthy Males and Females
NCT01475136A Study of LY2140023 in Hepatically-Impaired Participants
NCT01452919A Physical Dependence Study in Schizophrenia
NCT01354353A Study of Safety and Tolerability in Subjects With Schizophrenia
NCT01328093A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients
NCT01307800A Study of LY2140023 in Patients With Schizophrenia
NCT01125358A Study in Schizophrenic Patients
NCT01052103A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
NCT00845026A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients
NCT00149292Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo
NCT06264388A Biomarker-Guided Phase 2 Study of DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) Extended-Release Tablets